Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib + Chemo in Japanese Newly Diagnosed AML
NCT02834390Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of quizartinib in acute myeloid leukemia (AML) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Summary of Best Responses up to 1 year, Maximum Serum Concentration and 7 more. Started Aug 2016; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02834390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834390.